This work provides the first atomic-level explanation for statin-induced myopathy and reveals why individuals with RyR1 gain-of-function variants—already known to be overrepresented among statin-intolerant patients—are particularly vulnerable to muscle toxicity. This evidence concerns the gene RYR1 and myopathy.